Gamma Medica has established partnerships with Philips Healthcare and Volpara Solutions. Gamma Medica will offer Philips' MicroDose SI full-field digital mammography technology as an adjunct to its LumaGem molecular breast imaging platform, although Philips' technology will continue to be marketed as a standalone product. The deal with Volpara involves the use of VolparaDensity technology to allow the adoption of protocols based on breast density.
Progress against cancer has been shrouded by better outcomes in other areas of medicine, researchers report. "As fewer and fewer people die from heart disease, stroke and accidents, more and more people are alive long enough to be at risk of developing and dying from cancer," said researcher Samir Soneji. The analysis looked at cancer mortality in the context of progress on other diseases, and researchers found substantial progress in cancer outcomes. The work was published in the Journal of Clinical Oncology.
CHC Healthcare Group has gained the rights to sell Novadaq imaging devices to hospitals in Taiwan and China. CHC will begin importing and selling Novadaq equipment by the end of June in Taiwan and within six to nine months in China, according to a spokeswoman.
A final rule from the FDA requires that applications for premarket approval of medical devices cover data on patients 21 and younger. The agency does not anticipate a significant economic impact because the rule doesn't require added clinical research but only a summary of "readily available" information.
The budget bill signed into law last week included funding for Alzheimer's disease research, outreach, education and caregiver support. The appropriations include an additional $100 million for Alzheimer's research awarded to the National Institute on Aging.